PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
10.4167/jbv.2019.49.4.230
- Author:
Mst Shanta ISLAM TULTUL
1
;
Young Sang KOH
Author Information
1. Department of Microbiology and Immunology, School of Medicine and Brain Korea 21 PLUS Program, and Jeju Research Center for Natural Medicine, Jeju National University, Jeju, Korea. yskoh7@jejunu.ac.kr
- Publication Type:Review
- Keywords:
PD-1;
Tumour-associated macrophages;
Colon cancer
- MeSH:
Animals;
Breast Neoplasms;
Cell Death;
Colon;
Colonic Neoplasms;
Cytophagocytosis;
Immunotherapy;
Life Expectancy;
Lymphocytes;
Macrophages;
Mice;
Phagocytosis;
Skin;
T-Lymphocytes;
United Nations
- From:Journal of Bacteriology and Virology
2019;49(4):230-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Programmed cell death protein 1 (PD-1) is an immuno-inhibitory cell surface receptor protein of the myeloid, and lymphoid cell. PD-L1 is the ligand of PD-1, which is abundant in different malignant tissue e.g. skin, colon and breast cancer. PD-1/PD-L1 interaction helps the tumour cell to escape from the immune response by limiting TCR mediated T lymphocytes proliferation. Recently, PD-1 or PD-L1 blocking immunotherapy proved their efficacy in the treatment of different cancers. However, PD-1/PD-L1 interaction is well studied in T lymphocytes, but little is known about its function in tumour-associated macrophages (TAMs). In the tumour microenvironment, phagocytosis by TAMs plays a vital role in the immune response. In this review, the significance of PD-1 expression by TAMs and how it influences tumour immunity will be discussed. Recently, it has been found that PD-1 can express by TAMs and its expression level is directly related to duration and stages of colon cancer. TAMs expression of PD-1 was shown to be related to significant depletion of cancer cell phagocytosis. Monoclonal antibody against either PD-1 or PD-L1 in mice model of colon cancer promotes tumour cell phagocytosis by TAMs, thereby limiting the growth of the tumour and increase life expectancy. Therefore, PD-1 can be a promising target in macrophage-mediated immune therapy.
